Clinical trials: Patients with Multiple Sclerosis
Amyotrophic Lateral Sclerosis
Study of Safety and Proof of the Mechanism of BLZ945 in ALS Patients
It was an open label study to evaluate safety, tolerability and brain microglia response in participants with Amyotrophic Lateral Sclerosis (ALS) following multiple doses of BLZ945.
- Trial name
- NCT04066244
- Testing
- BLZ945
- Where
- 4 sites in United States, Finland and 1 more
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Chronic Progressive
China Betaferon Adherence, Coping and Nurse Support Study
Non-adherence reduces treatment benefit and can bias the assessment of treatment efficacy thereby involving safety risks for the patient and influencing health cost-effectiveness.
- Trial name
- NCT01436838
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Bayer
Renal Angiomyolipoma
Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.
The purpose of this study was to assess the safety and efficacy of everolimus (Afinitor®) in Chinese patients with renal angiomyolipoma (AML) associated with tuberous sclerosis complex (TSC).
- Trial name
- NCT03525834
- Testing
- Everolimus
- Where
- 5 sites in China
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting
A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
This is a phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex (interferon beta-1a) controlled dose finding study to evaluate the efficacy as measured by brain MRI lesions, and safety of 2 dose…
- Trial name
- NCT00676715
- Testing
- Ocrelizumab, Avonex
- Where
- 84 sites in United States, Belgium and 16 more
- Volunteers
- 220 people
- Sponsor
- Genentech, Inc.
Relapsing-remitting Multiple Sclerosis
Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMS
A 6 months prospective, randomized, multicenter, controlled, parallel-group, open-label study in RRMS patients to assess the impact of an individualized patient support program (PSP) on treatment satisfaction and to evaluate…
- Trial name
- STAY (NCT01709812)
- Testing
- individualized patient support program, Standard care
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
A Study of Treatment Patterns and Annualized Relapse Rate in Multiple Sclerosis Patients Who Escalate Versus Continue Disease-Modifying Therapies Following Relapse
The aim of this study was to describe real-world treatment patterns after relapsing on platform disease-modifying therapies (DMTs) in terms of proportions of patients who remain on platform DMTs or escalate to high-efficacy DMTs…
- Trial name
- NCT07743281
- Where
- United States
- Volunteers
- 753 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
This randomized, double-blind, double-dummy, parallel-group study will evaluate the efficacy and safety of ocrelizumab in comparison with interferon beta-1a (Rebif) in participants with relapsing multiple sclerosis.
- Trial name
- NCT01247324
- Testing
- Interferon beta-1a, Ocrelizumab
- Where
- 142 sites in United States, Argentina and 30 more
- Volunteers
- 821 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis, Muscle Spasticity
Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity.
This study is being conducted to compare the impact of somnolence (sleepiness) on cognition (awareness) as well as the safety and effectiveness of tizanidine hydrochloride capsules versus Zanaflex® (tizanidine hydrochloride…
- Conditions
- Multiple Sclerosis, Muscle Spasticity, Spinal Cord Injury, Stroke
- Trial name
- NCT00047580
- Testing
- tizanidine hydrochloride capsule
- Where
- 16 sites in United States
- Volunteers
- 120 people
- Sponsor
- Elan Pharmaceuticals
Multiple Sclerosis
A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)
The main purpose of the study is to evaluate participant satisfaction after administration of ocrelizumab subcutaneously (SC) after 12 months using the therapy administration satisfaction questionnaire subcutaneous (TASQ-SC).
- Trial name
- SurfSubQ (NCT06780150)
- Testing
- Ocrelizumab
- Where
- 93 sites in Germany, Switzerland
- Volunteers
- 842 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis, Relapsing-Remitting
Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®
The study is planned to evaluate the cognitive functions in subjects with RRMS treated with interferon beta-1a, and its relationship to the fatigue and neurological dysfunction status.
- Trial name
- SKORE (NCT01075880)
- Testing
- Rebif (Interferon beta-1a)
- Where
- 13 sites in Czechia
- Volunteers
- 300 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Relapsing-Remitting
Fingolimod -Response According to Coping - Evaluation
This is a prospective, open-label, multi-center phase IV study to assess response to fingolimod initiation according to coping profile in adult patients with highly active relapsing remitting multiple sclerosis in France.
- Trial name
- GRACE (NCT01420055)
- Testing
- fingolimod
- Where
- 47 sites in France
- Volunteers
- 189 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy
This study is to find out the safety and effectiveness of Avonex (interferon-beta-1a) Therapy in patients who have developed neutralizing antibodies during previous interferon-beta treatment
- Trial name
- SAFE (NCT00493077)
- Testing
- low immunogenic interferon-beta-1a
- Where
- 5 sites in Sweden
- Volunteers
- 3 people
- Sponsor
- Biogen
Amyotrophic Lateral Sclerosis (ALS)
Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis
The purpose of this study is to determine whether nine months of administration of creatine monohydrate results in an increase in muscle strength in patients with amyotrophic lateral sclerosis (ALS).
- Trial name
- NCT00069186
- Testing
- Creatine Monohydrate
- Where
- 8 sites in United States
- Volunteers
- 107 people
- Sponsor
- The Avicena Group
Systemic Sclerosis, Scleroderma
Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Participants With Systemic Sclerosis
This study investigates the efficacy and safety of STI571 for the treatment of fibrosis in participants with systemic sclerosis.
- Trial name
- NCT00613171
- Testing
- STI571
- Where
- 7 sites in United States, Germany and 3 more
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri
The primary objective of the study is to evaluate the safety of natalizumab use in the pediatric multiple sclerosis (MS) population.
- Trial name
- NCT02137109
- Testing
- natalizumab
- Volunteers
- 400 people
- Sponsor
- Biogen
Non-Active Secondary Progressive Multiple Sclerosis
Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis
Only subjects that have completed TILS-021, a Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose-Ranging Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients are eligible…
- Trial name
- TILS-022 (NCT06890923)
- Testing
- Foralumab TZLS-401 100 µg
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Tiziana Life Sciences LTD
Multiple Sclerosis
An Observational Study to Assess the Quality of Life of the Patients With Multiple Sclerosis and Their Caregivers
This is an observational, non controlled, non-interventional, multicentric, prospective study planned to be conducted in 450 subjects diagnosed with MS and their caregivers in 20 centres of Argentina.
- Trial name
- NCT01075737
- Where
- Argentina
- Volunteers
- 141 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
Depression and Fatigue in MS Patients Treated With Betaferon.
This study aims to evaluate the occurence and severity of fatigue and depression in multiple sclerosis patients and the impact of Betaferon treatment on symptoms alterations.
- Trial name
- FADO (NCT01354665)
- Testing
- Interferon beta-1b (Betaferon, BAY86-5046)
- Where
- Poland
- Volunteers
- 567 people
- Sponsor
- Bayer
Multiple Sclerosis, Relapsing-Remitting
RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial
To observe the safety and effectivity of a Recombinant Human B Lymphocyte Stimulator Receptor : Immunoglobulin G( IgG ) Fc Fusion Protein for injection (RC18) in patients with relapsing remitting multiple sclerosis, analyze the…
- Trial name
- NCT04625153
- Testing
- RC18 160mg, RC18 240mg
- Where
- China
- Volunteers
- 8 people
- Sponsor
- RemeGen Co., Ltd.
Multiple Sclerosis
Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis
This study evaluates the use of single agent ublituximab, a novel monoclonal antibody, in participants with relapsing forms of multiple sclerosis.
- Trial name
- NCT02738775
- Testing
- Ublituximab
- Where
- 12 sites in United States
- Volunteers
- 49 people
- Sponsor
- TG Therapeutics, Inc.